Vol. 2 No. 10 (2022)
Reimbursement Reviews

Lenvatinib and Pembrolizumab (Lenvima and Keytruda)

Published October 11, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Lenvima (lenvatinib) 20 mg (two 10 mg capsules) orally once daily in combination with Keytruda (pembrolizumab) administered as an IV infusion over 30 minutes every 3 weeks.
  • Indication: In combination with pembrolizumab, for the treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC with no prior systemic therapy for metastatic RCC.